Objective: This work aims to elucidate the identification of homologs of miRNAs in a pronormal stage of Parkinson`s disease.
Background: Parkinson’s disease (PD) is defined by the exclusion of dopaminergic neurons in the substantia nigra, which causes motor symptoms such as bradykinesia, stiffness, and tremors. Clinical symptoms and neuropathology have typically been used to make a diagnosis. However, there is an increasing interest in discovering peripheral biomarkers of Parkinson`s disease.
Exosomal miRNAs have emerged as possible diagnostic biomarkers for neurodegenerative disorders because of their stability and clinical specificity. They provide an edge over other biomarkers by reflecting changes in the nervous system microenvironment. Exosomal miRNAs have an important role in disorders such as Parkinson`s Disease, Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD), where they contribute to disease development by transmitting misfolded proteins and participating in pathogenesis
Method: The drug-induced Parkinson`s disease model (DIPD) has been successfully implemented in rats. We extracted exosomes from serum and characterized them using TEM, NTA, and Western Blot for particular markers as described before. After characterising exosomes, we performed deep sequence analysis of SE 30 million reads using Illumina (Nova Seq 6000). Following data processing, DEmiRNAs were analysed using the DESeq2 R program. Later, we confirmed dysregulated miRNAs (miR-199a, miR-351, and miR-1b) using qPCR and compared them to our own existing serum-based miRNA data. We also discovered homologs of miRNAs exclusively present during the prodromal condition
Results: In this work, deep sequencing and bioinformatics tools identified characteristic homologs of miRNAs (miR-199a, miR-351, and miR-1b), which we then validated by qPCR.
Conclusion: Preclinical studies on serum-based exosomal miRNAs in prodromal conditions of drug-induced Parkinson’s Disease focus on utilizing miRNA profiles in exosomes as non-invasive biomarkers for early diagnosis of PD.
To cite this abstract in AMA style:
M. Ahmad. Preclinical Studies: Investigating Serum-Based Exosomal miRNAs in Prodromal Drug-Induced Parkinson’s Disease [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/preclinical-studies-investigating-serum-based-exosomal-mirnas-in-prodromal-drug-induced-parkinsons-disease/. Accessed October 9, 2024.« Back to 2024 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/preclinical-studies-investigating-serum-based-exosomal-mirnas-in-prodromal-drug-induced-parkinsons-disease/